This report aims to provide a comprehensive presentation of the global market for Tumor Necrosis Factor Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Necrosis Factor Inhibitors. This report contains market size and forecasts of Tumor Necrosis Factor Inhibitors in global, including the following market information:
Global Tumor Necrosis Factor Inhibitors Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Tumor Necrosis Factor Inhibitors Market Sales, 2018-2023, 2024-2032, (K Pcs)
Global top five Tumor Necrosis Factor Inhibitors companies in 2022 (%)
The global Tumor Necrosis Factor Inhibitors market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Humira Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Tumor Necrosis Factor Inhibitors include EPIRUS Biopharmaceuticals, Bionovis, CASI Pharmaceuticals, Janssen Biotech, Momenta Pharmaceuticals, GlaxoSmithKline, HanAll Biopharma, Intas Pharmaceuticals and LEO Pharma, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tumor Necrosis Factor Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor Necrosis Factor Inhibitors Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Tumor Necrosis Factor Inhibitors Market Segment Percentages, by Type, 2022 (%)
Humira
Enbrel
Remicade
Others
Global Tumor Necrosis Factor Inhibitors Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Tumor Necrosis Factor Inhibitors Market Segment Percentages, by Application, 2022 (%)
Alzheimer's Diseases
Parkinson's Diseases
Ischemic Stroke
Multiple Sclerosis
Others
Global Tumor Necrosis Factor Inhibitors Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Pcs)
Global Tumor Necrosis Factor Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Necrosis Factor Inhibitors revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Tumor Necrosis Factor Inhibitors revenues share in global market, 2022 (%)
Key companies Tumor Necrosis Factor Inhibitors sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Tumor Necrosis Factor Inhibitors sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
EPIRUS Biopharmaceuticals
Bionovis
CASI Pharmaceuticals
Janssen Biotech
Momenta Pharmaceuticals
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
Dexa Medica
LG Life Sciences
MedImmune
Outline of Major Chapters:
Chapter 1: Introduces the definition of Tumor Necrosis Factor Inhibitors, market overview.
Chapter 2: Global Tumor Necrosis Factor Inhibitors market size in revenue and volume.
Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tumor Necrosis Factor Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Tumor Necrosis Factor Inhibitors capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Tumor Necrosis Factor Inhibitors Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Tumor Necrosis Factor Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Tumor Necrosis Factor Inhibitors Overall Market Size
2.1 Global Tumor Necrosis Factor Inhibitors Market Size: 2022 VS 2030
2.2 Global Tumor Necrosis Factor Inhibitors Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Tumor Necrosis Factor Inhibitors Sales: 2018-2030
3 Company Landscape
3.1 Top Tumor Necrosis Factor Inhibitors Players in Global Market
3.2 Top Global Tumor Necrosis Factor Inhibitors Companies Ranked by Revenue
3.3 Global Tumor Necrosis Factor Inhibitors Revenue by Companies
3.4 Global Tumor Necrosis Factor Inhibitors Sales by Companies
3.5 Global Tumor Necrosis Factor Inhibitors Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Tumor Necrosis Factor Inhibitors Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Tumor Necrosis Factor Inhibitors Product Type
3.8 Tier 1, Tier 2 and Tier 3 Tumor Necrosis Factor Inhibitors Players in Global Market
3.8.1 List of Global Tier 1 Tumor Necrosis Factor Inhibitors Companies
3.8.2 List of Global Tier 2 and Tier 3 Tumor Necrosis Factor Inhibitors Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Tumor Necrosis Factor Inhibitors Market Size Markets, 2022 & 2030
4.1.2 Humira
4.1.3 Enbrel
4.1.4 Remicade
4.1.5 Others
4.2 By Type - Global Tumor Necrosis Factor Inhibitors Revenue & Forecasts
4.2.1 By Type - Global Tumor Necrosis Factor Inhibitors Revenue, 2018-2023
4.2.2 By Type - Global Tumor Necrosis Factor Inhibitors Revenue, 2024-2030
4.2.3 By Type - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
4.3 By Type - Global Tumor Necrosis Factor Inhibitors Sales & Forecasts
4.3.1 By Type - Global Tumor Necrosis Factor Inhibitors Sales, 2018-2023
4.3.2 By Type - Global Tumor Necrosis Factor Inhibitors Sales, 2024-2030
4.3.3 By Type - Global Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
4.4 By Type - Global Tumor Necrosis Factor Inhibitors Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Tumor Necrosis Factor Inhibitors Market Size, 2022 & 2030
5.1.2 Alzheimer's Diseases
5.1.3 Parkinson's Diseases
5.1.4 Ischemic Stroke
5.1.5 Multiple Sclerosis
5.1.6 Others
5.2 By Application - Global Tumor Necrosis Factor Inhibitors Revenue & Forecasts
5.2.1 By Application - Global Tumor Necrosis Factor Inhibitors Revenue, 2018-2023
5.2.2 By Application - Global Tumor Necrosis Factor Inhibitors Revenue, 2024-2030
5.2.3 By Application - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
5.3 By Application - Global Tumor Necrosis Factor Inhibitors Sales & Forecasts
5.3.1 By Application - Global Tumor Necrosis Factor Inhibitors Sales, 2018-2023
5.3.2 By Application - Global Tumor Necrosis Factor Inhibitors Sales, 2024-2030
5.3.3 By Application - Global Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
5.4 By Application - Global Tumor Necrosis Factor Inhibitors Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Tumor Necrosis Factor Inhibitors Market Size, 2022 & 2030
6.2 By Region - Global Tumor Necrosis Factor Inhibitors Revenue & Forecasts
6.2.1 By Region - Global Tumor Necrosis Factor Inhibitors Revenue, 2018-2023
6.2.2 By Region - Global Tumor Necrosis Factor Inhibitors Revenue, 2024-2030
6.2.3 By Region - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
6.3 By Region - Global Tumor Necrosis Factor Inhibitors Sales & Forecasts
6.3.1 By Region - Global Tumor Necrosis Factor Inhibitors Sales, 2018-2023
6.3.2 By Region - Global Tumor Necrosis Factor Inhibitors Sales, 2024-2030
6.3.3 By Region - Global Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Tumor Necrosis Factor Inhibitors Revenue, 2018-2030
6.4.2 By Country - North America Tumor Necrosis Factor Inhibitors Sales, 2018-2030
6.4.3 US Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.4.4 Canada Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.4.5 Mexico Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Tumor Necrosis Factor Inhibitors Revenue, 2018-2030
6.5.2 By Country - Europe Tumor Necrosis Factor Inhibitors Sales, 2018-2030
6.5.3 Germany Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5.4 France Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5.5 U.K. Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5.6 Italy Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5.7 Russia Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5.8 Nordic Countries Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.5.9 Benelux Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Tumor Necrosis Factor Inhibitors Revenue, 2018-2030
6.6.2 By Region - Asia Tumor Necrosis Factor Inhibitors Sales, 2018-2030
6.6.3 China Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.6.4 Japan Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.6.5 South Korea Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.6.6 Southeast Asia Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.6.7 India Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Tumor Necrosis Factor Inhibitors Revenue, 2018-2030
6.7.2 By Country - South America Tumor Necrosis Factor Inhibitors Sales, 2018-2030
6.7.3 Brazil Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.7.4 Argentina Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Sales, 2018-2030
6.8.3 Turkey Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.8.4 Israel Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.8.5 Saudi Arabia Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
6.8.6 UAE Tumor Necrosis Factor Inhibitors Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 EPIRUS Biopharmaceuticals
7.1.1 EPIRUS Biopharmaceuticals Company Summary
7.1.2 EPIRUS Biopharmaceuticals Business Overview
7.1.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Major Product Offerings
7.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.1.5 EPIRUS Biopharmaceuticals Key News & Latest Developments
7.2 Bionovis
7.2.1 Bionovis Company Summary
7.2.2 Bionovis Business Overview
7.2.3 Bionovis Tumor Necrosis Factor Inhibitors Major Product Offerings
7.2.4 Bionovis Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.2.5 Bionovis Key News & Latest Developments
7.3 CASI Pharmaceuticals
7.3.1 CASI Pharmaceuticals Company Summary
7.3.2 CASI Pharmaceuticals Business Overview
7.3.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Major Product Offerings
7.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.3.5 CASI Pharmaceuticals Key News & Latest Developments
7.4 Janssen Biotech
7.4.1 Janssen Biotech Company Summary
7.4.2 Janssen Biotech Business Overview
7.4.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Major Product Offerings
7.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.4.5 Janssen Biotech Key News & Latest Developments
7.5 Momenta Pharmaceuticals
7.5.1 Momenta Pharmaceuticals Company Summary
7.5.2 Momenta Pharmaceuticals Business Overview
7.5.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Major Product Offerings
7.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.5.5 Momenta Pharmaceuticals Key News & Latest Developments
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Company Summary
7.6.2 GlaxoSmithKline Business Overview
7.6.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Major Product Offerings
7.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.6.5 GlaxoSmithKline Key News & Latest Developments
7.7 HanAll Biopharma
7.7.1 HanAll Biopharma Company Summary
7.7.2 HanAll Biopharma Business Overview
7.7.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Major Product Offerings
7.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.7.5 HanAll Biopharma Key News & Latest Developments
7.8 Intas Pharmaceuticals
7.8.1 Intas Pharmaceuticals Company Summary
7.8.2 Intas Pharmaceuticals Business Overview
7.8.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Major Product Offerings
7.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.8.5 Intas Pharmaceuticals Key News & Latest Developments
7.9 LEO Pharma
7.9.1 LEO Pharma Company Summary
7.9.2 LEO Pharma Business Overview
7.9.3 LEO Pharma Tumor Necrosis Factor Inhibitors Major Product Offerings
7.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.9.5 LEO Pharma Key News & Latest Developments
7.10 Dexa Medica
7.10.1 Dexa Medica Company Summary
7.10.2 Dexa Medica Business Overview
7.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Major Product Offerings
7.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.10.5 Dexa Medica Key News & Latest Developments
7.11 LG Life Sciences
7.11.1 LG Life Sciences Company Summary
7.11.2 LG Life Sciences Tumor Necrosis Factor Inhibitors Business Overview
7.11.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Major Product Offerings
7.11.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.11.5 LG Life Sciences Key News & Latest Developments
7.12 MedImmune
7.12.1 MedImmune Company Summary
7.12.2 MedImmune Tumor Necrosis Factor Inhibitors Business Overview
7.12.3 MedImmune Tumor Necrosis Factor Inhibitors Major Product Offerings
7.12.4 MedImmune Tumor Necrosis Factor Inhibitors Sales and Revenue in Global (2018-2023)
7.12.5 MedImmune Key News & Latest Developments
8 Global Tumor Necrosis Factor Inhibitors Production Capacity, Analysis
8.1 Global Tumor Necrosis Factor Inhibitors Production Capacity, 2018-2030
8.2 Tumor Necrosis Factor Inhibitors Production Capacity of Key Manufacturers in Global Market
8.3 Global Tumor Necrosis Factor Inhibitors Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Tumor Necrosis Factor Inhibitors Supply Chain Analysis
10.1 Tumor Necrosis Factor Inhibitors Industry Value Chain
10.2 Tumor Necrosis Factor Inhibitors Upstream Market
10.3 Tumor Necrosis Factor Inhibitors Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Tumor Necrosis Factor Inhibitors Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Tumor Necrosis Factor Inhibitors in Global Market
Table 2. Top Tumor Necrosis Factor Inhibitors Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Tumor Necrosis Factor Inhibitors Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Tumor Necrosis Factor Inhibitors Revenue Share by Companies, 2018-2023
Table 5. Global Tumor Necrosis Factor Inhibitors Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Tumor Necrosis Factor Inhibitors Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Tumor Necrosis Factor Inhibitors Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Tumor Necrosis Factor Inhibitors Product Type
Table 9. List of Global Tier 1 Tumor Necrosis Factor Inhibitors Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Tumor Necrosis Factor Inhibitors Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Tumor Necrosis Factor Inhibitors Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Tumor Necrosis Factor Inhibitors Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Tumor Necrosis Factor Inhibitors Sales (K Pcs), 2018-2023
Table 15. By Type - Global Tumor Necrosis Factor Inhibitors Sales (K Pcs), 2024-2030
Table 16. By Application ? Global Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Tumor Necrosis Factor Inhibitors Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Tumor Necrosis Factor Inhibitors Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Tumor Necrosis Factor Inhibitors Sales (K Pcs), 2018-2023
Table 20. By Application - Global Tumor Necrosis Factor Inhibitors Sales (K Pcs), 2024-2030
Table 21. By Region ? Global Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Tumor Necrosis Factor Inhibitors Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Tumor Necrosis Factor Inhibitors Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Tumor Necrosis Factor Inhibitors Sales (K Pcs), 2018-2023
Table 25. By Region - Global Tumor Necrosis Factor Inhibitors Sales (K Pcs), 2024-2030
Table 26. By Country - North America Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2024-2030
Table 30. By Country - Europe Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2024-2030
Table 34. By Region - Asia Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2024-2030
Table 38. By Country - South America Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2024-2030
Table 42. By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Sales, (K Pcs), 2024-2030
Table 46. EPIRUS Biopharmaceuticals Company Summary
Table 47. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Product Offerings
Table 48. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. EPIRUS Biopharmaceuticals Key News & Latest Developments
Table 50. Bionovis Company Summary
Table 51. Bionovis Tumor Necrosis Factor Inhibitors Product Offerings
Table 52. Bionovis Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Bionovis Key News & Latest Developments
Table 54. CASI Pharmaceuticals Company Summary
Table 55. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offerings
Table 56. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. CASI Pharmaceuticals Key News & Latest Developments
Table 58. Janssen Biotech Company Summary
Table 59. Janssen Biotech Tumor Necrosis Factor Inhibitors Product Offerings
Table 60. Janssen Biotech Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Janssen Biotech Key News & Latest Developments
Table 62. Momenta Pharmaceuticals Company Summary
Table 63. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offerings
Table 64. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Momenta Pharmaceuticals Key News & Latest Developments
Table 66. GlaxoSmithKline Company Summary
Table 67. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Product Offerings
Table 68. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. GlaxoSmithKline Key News & Latest Developments
Table 70. HanAll Biopharma Company Summary
Table 71. HanAll Biopharma Tumor Necrosis Factor Inhibitors Product Offerings
Table 72. HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. HanAll Biopharma Key News & Latest Developments
Table 74. Intas Pharmaceuticals Company Summary
Table 75. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Product Offerings
Table 76. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Intas Pharmaceuticals Key News & Latest Developments
Table 78. LEO Pharma Company Summary
Table 79. LEO Pharma Tumor Necrosis Factor Inhibitors Product Offerings
Table 80. LEO Pharma Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. LEO Pharma Key News & Latest Developments
Table 82. Dexa Medica Company Summary
Table 83. Dexa Medica Tumor Necrosis Factor Inhibitors Product Offerings
Table 84. Dexa Medica Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. Dexa Medica Key News & Latest Developments
Table 86. LG Life Sciences Company Summary
Table 87. LG Life Sciences Tumor Necrosis Factor Inhibitors Product Offerings
Table 88. LG Life Sciences Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. LG Life Sciences Key News & Latest Developments
Table 90. MedImmune Company Summary
Table 91. MedImmune Tumor Necrosis Factor Inhibitors Product Offerings
Table 92. MedImmune Tumor Necrosis Factor Inhibitors Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. MedImmune Key News & Latest Developments
Table 94. Tumor Necrosis Factor Inhibitors Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 95. Global Tumor Necrosis Factor Inhibitors Capacity Market Share of Key Manufacturers, 2021-2023
Table 96. Global Tumor Necrosis Factor Inhibitors Production by Region, 2018-2023 (K Pcs)
Table 97. Global Tumor Necrosis Factor Inhibitors Production by Region, 2024-2030 (K Pcs)
Table 98. Tumor Necrosis Factor Inhibitors Market Opportunities & Trends in Global Market
Table 99. Tumor Necrosis Factor Inhibitors Market Drivers in Global Market
Table 100. Tumor Necrosis Factor Inhibitors Market Restraints in Global Market
Table 101. Tumor Necrosis Factor Inhibitors Raw Materials
Table 102. Tumor Necrosis Factor Inhibitors Raw Materials Suppliers in Global Market
Table 103. Typical Tumor Necrosis Factor Inhibitors Downstream
Table 104. Tumor Necrosis Factor Inhibitors Downstream Clients in Global Market
Table 105. Tumor Necrosis Factor Inhibitors Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Segment by Type in 2022
Figure 2. Tumor Necrosis Factor Inhibitors Segment by Application in 2022
Figure 3. Global Tumor Necrosis Factor Inhibitors Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Tumor Necrosis Factor Inhibitors Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Tumor Necrosis Factor Inhibitors Revenue, 2018-2030 (US$, Mn)
Figure 7. Tumor Necrosis Factor Inhibitors Sales in Global Market: 2018-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Tumor Necrosis Factor Inhibitors Revenue in 2022
Figure 9. By Type - Global Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 11. By Type - Global Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 12. By Type - Global Tumor Necrosis Factor Inhibitors Price (USD/Pcs), 2018-2030
Figure 13. By Application - Global Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 15. By Application - Global Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 16. By Application - Global Tumor Necrosis Factor Inhibitors Price (USD/Pcs), 2018-2030
Figure 17. By Region - Global Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 20. By Region - Global Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 21. By Country - North America Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 22. By Country - North America Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 23. US Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 28. Germany Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 29. France Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 37. China Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 41. India Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 43. By Country - South America Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 44. Brazil Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Tumor Necrosis Factor Inhibitors Sales Market Share, 2018-2030
Figure 48. Turkey Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Tumor Necrosis Factor Inhibitors Revenue, (US$, Mn), 2018-2030
Figure 52. Global Tumor Necrosis Factor Inhibitors Production Capacity (K Pcs), 2018-2030
Figure 53. The Percentage of Production Tumor Necrosis Factor Inhibitors by Region, 2022 VS 2030
Figure 54. Tumor Necrosis Factor Inhibitors Industry Value Chain
Figure 55. Marketing Channels
